STOCK TITAN

Innate Pharma S.A. ADS - IPHA STOCK NEWS

Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.

Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.

The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.

Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.

The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.

With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.

Rhea-AI Summary

Innate Pharma has presented preliminary data at the EORTC CLTG annual meeting, demonstrating promising clinical responses from its anti-KIR3DL2 antibody, lacutamab, in patients with mycosis fungoides (MF) who have undergone previous systemic therapies. The Phase 2 TELLOMAK trial revealed a global objective response rate of 28.6% in KIR3DL2-expressing patients, with a favorable safety profile. The company anticipates sharing final data from this trial in 2023, alongside ongoing studies for other lymphomas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
-
Rhea-AI Summary

Innate Pharma reported consolidated financial results for the first half of 2022, showcasing a net income of €6.3 million compared to a net loss of €23.7 million in the same period last year. Revenue surged to €45.6 million, primarily driven by milestone payments and collaborations with AstraZeneca and Sanofi. Notably, the company advanced the anti-CD39 monoclonal antibody IPH5201 into Phase 2 trials and received a €3 million milestone for IPH6401/sar514. With a strong cash position of €158.2 million, Innate is well-funded through H2 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
-
Rhea-AI Summary

Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced a conference call scheduled for September 15, 2022, at 2 p.m. CEST to discuss its business progress in the first half of 2022. The call will feature CEO Mondher Mahjoubi and other executives. A live webcast will be available, with a replay accessible on the company’s website for 90 days post-event. Innate Pharma focuses on clinical-stage oncology therapies, leveraging its expertise in immune system targeting to develop innovative antibody treatments. Visit www.innate-pharma.com for more details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced key presentations at the ESMO Annual Meeting 2022 in Paris from September 9-13. Highlights include:

  • Poster Presentation: Ongoing Phase 1b trial of lacutamab for peripheral T-cell lymphoma.
  • Oral Presentation: ANKET platform by Eric Vivier focusing on multispecific antibodies for NK cell activation.
  • Mini Oral Presentation: AstraZeneca's Phase 2 NeoCOAST study on durvalumab in early-stage NSCLC.

Lacutamab targets KIR3DL2 expressed in certain aggressive lymphomas, showcasing Innate's innovative approaches in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced participation in investor conferences, including Citi's 17th Annual BioPharma Conference on September 7-8, 2022, and H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022. The company, focused on oncology, is advancing several first-in-class therapeutic antibodies aimed at enhancing cancer treatment outcomes. With a strong pipeline and partnerships with major biopharmaceutical leaders, Innate is committed to improving patient care in high unmet medical need areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences
-
Rhea-AI Summary

Innate Pharma has released its total number of shares outstanding and voting rights as of August 1, 2022. The company has 79,893,019 ordinary shares and 6,514 preferred shares from 2016 and 7,581 from 2017. The total theoretical voting rights stand at 80,650,859, with exercisable voting rights at 80,632,284. This disclosure is in compliance with French regulations to ensure transparency for shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Innate Pharma announced that the INTERLINK-1 Phase 3 study, sponsored by AstraZeneca, did not meet the efficacy threshold during an interim analysis and will be discontinued. The trial evaluated monalizumab with cetuximab against cetuximab alone for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Despite this setback, Innate remains optimistic about monalizumab's potential in lung cancer and continues to focus on ongoing studies like PACIFIC-9 and NeoCOAST-2. AstraZeneca will share data from the trial in the future.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.19%
Tags
-
Rhea-AI Summary

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced participation in the upcoming BTIG Biotechnology Conference scheduled for August 8-9, 2022 in New York. The company is focused on developing therapeutic antibodies to improve oncology treatments. With a diverse pipeline of clinical and preclinical candidates, Innate is recognized for its expertise in Natural Killer cell biology and partnerships with major biopharmaceutical companies such as Bristol-Myers Squibb and AstraZeneca. For more information, visit www.innate-pharma.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
conferences
-
Rhea-AI Summary

Innate Pharma has announced that Sanofi is progressing IPH6401/SAR’514 into investigational new drug enabling studies, triggering a €3 million milestone payment. This BCMA-targeting NK cell engager utilizes Sanofi’s CROSSODILE platform, combined with Innate’s ANKET technology, to enhance NK cell activation for cancer therapy. IPH6401/SAR’514 has demonstrated anti-tumor activity in preclinical models, with Sanofi overseeing its development, manufacturing, and commercialization. The collaboration may yield up to €400 million in further development milestones and royalties for Innate.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
Rhea-AI Summary

Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced its participation in the Portzamparc Corporate Access event in Paris on June 30, 2022. The company is a clinical-stage biotech firm focused on oncology, aiming to improve cancer treatments through antibody therapies that utilize the immune system. Innate has a diverse pipeline of clinical candidates and partnerships with leading pharmaceutical companies, including Bristol-Myers Squibb and AstraZeneca. Headquartered in Marseille, France, Innate continues to advance its research and collaboration efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of Innate Pharma S.A. ADS (IPHA)?

The current stock price of Innate Pharma S.A. ADS (IPHA) is $2.05 as of December 20, 2024.

What is the market cap of Innate Pharma S.A. ADS (IPHA)?

The market cap of Innate Pharma S.A. ADS (IPHA) is approximately 170.5M.

What does Innate Pharma S.A. specialize in?

Innate Pharma S.A. specializes in immuno-oncology, developing therapeutic antibodies to enhance the innate immune system's ability to fight cancer.

What are some of Innate Pharma's key products?

Key products include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501.

How does Innate Pharma generate revenue?

The company generates revenue through research collaborations, licensing agreements, and milestone payments from pharmaceutical companies.

Who are some of Innate Pharma's notable partners?

Innate Pharma collaborates with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.

What is ANKET?

ANKET stands for Antibody-based NK cell Engager Therapeutics, Innate Pharma's proprietary platform for developing innovative cancer treatments.

What is the focus of Innate Pharma’s current projects?

Current projects focus on developing first-in-class antibodies and checkpoint inhibitors to address various cancer indications.

What stage is Innate Pharma in?

Innate Pharma is in the clinical stage, advancing multiple therapeutic candidates through clinical trials.

What makes Innate Pharma's approach unique?

Their unique expertise in natural killer cell biology and checkpoint inhibitors sets them apart in the field of immuno-oncology.

What is immuno-oncology?

Immuno-oncology is a field of cancer treatment that uses the body's immune system to detect and kill cancer cells.

How does Innate Pharma contribute to cancer research?

Innate Pharma contributes through innovative research and development of new therapies that harness the immune system to treat cancer.

Innate Pharma S.A. ADS

Nasdaq:IPHA

IPHA Rankings

IPHA Stock Data

170.53M
80.95M
0.5%
0.08%
Biotechnology
Healthcare
Link
United States of America
Marseille